Lenvervimab

Lenvervimab is a monoclonal antibody designed for the treatment of COVID-19. It was developed by Celltrion, a South Korean biopharmaceutical company. Lenvervimab is also known by its developmental code name, CT-P59.

Mechanism of Action

Lenvervimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to other monoclonal antibodies used in the treatment of COVID-19.

Clinical Trials

Lenvervimab has undergone Phase I, Phase II, and Phase III clinical trials. The results from these trials have shown that Lenvervimab is effective in reducing the severity of COVID-19 symptoms and the duration of the disease.

Approval

In February 2022, Lenvervimab was granted conditional approval by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of COVID-19.

Side Effects

As with all medications, Lenvervimab can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and diarrhea.

See Also

• COVID-19 pandemic
• COVID-19 vaccine
• Monoclonal antibodies for COVID-19

Lenvervimab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski